The device could upend treatment for the 33 million to 45 million Americans with severe allergies to food and other triggers.

FDA officials say this is the first epinephrine product for anaphylaxis that is not administered with a needle.

The FDA has approved a nasal spray, called neffy, to treat serious allergic reactions in adults and children who weigh at ...

SoundHealth launched a new feature in its AI-powered health care app that will give users personalized allergy forecasts to ...

A nasal spray developed ... Research shows the spray, recently approved in the EU and US, is just as effective at stopping ...

The FDA recently approved the first needle-free epinephrine product (neffy), an alternative to injectable epinephrine (EpiPen ...

ARS Pharmaceuticals' neffy, a needle-free nasal spray for allergies, receives FDA approval, driving stock price up 120%. Read ...

We came across a bullish thesis on ARS Pharmaceuticals (SPRY) on Value Degen’s Substack by Unemployed Value Degen. In this ...

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...